Press release

Press release

April 1, 2016

Announcement from Follicum’s Extraordinary General Meeting

The Meeting, held on April 1,  2016, approved the Board’s resolution to increase the company’s share capital through a rights issue, by gaining the required majority. The decision was taken to increase the company’s share capital by issuing a maximum of 6,001,938 new shares with a value of SEK 0.12 each, at a subscription price of […]

March 17, 2016

Notice of extraordinary general meeting of Follicum AB (publ)

The shareholders of Follicum AB (publ) are hereby given notice to attend an extraordinary general meeting to be held on Friday April 1, 2016 at 10.00 am at Scheelevägen 22 in Lund. Right to attend the general meeting Shareholders who wish to attend the extraordinära general meeting must be registered in the Euroclear Sweden AB share […]

March 17, 2016

Resolution to conduct a rights issue

On 15 March, board of directors of Follicum AB (publ) resolved to carry out a rights issue of 6 001 938 shares at an issue price of 5.00 SEK per share. At full subscription, this will raise approximately 30 MSEK of additional capital, before rights issue costs. The rights issue resolution of the board of […]

March 15, 2016

Positive results from Phase I of Follicum’s phase I/IIa clinical study reported

In early January 2016,  Follicum announced that the first healthy volunteer in the company’s clinical phase I/IIa study showed no negative effects after receiving the maximum dosage of FOL-005. Nine further healthy volunteers have now been given with the maximum dose and show the same positive results. This completes the first part of the phase […]

March 11, 2016

Follicum receives Allowance for Patent in the USA

On 10 March 2016 Follicum received a Notice of Allowance from the US Patent and Trademark Office regarding the patent application entitled “Novel Compositions and Uses Thereof”. The Notice of Allowance concerns the application for the lead drug candidate FOL-005 and related substances. The patent term lasts until at least 2032, with the possibility for […]

February 3, 2016

Maximum dose level achieved, in clinical phase I/IIa study, without complications

The maximum dose level in Follicum’s clinical phase I/IIa study has now been administered to the first healthy volunteer without any negative effects being seen, achieving the study’s initial dose escalating part without any problems. The clinical study was initiated on 19 January 2016. The first participant in the study was administered with the maximum […]

January 22, 2016

Follicum Announces First Healthy Volunteer Dosed With FOL-005

On 19 January 2016 the first healthy volunteer received treatment with FOL-005, initiating the clinical phase I/IIa safety/efficacy study according to Follicum’s previously communicated time plan. Previously FOL-005 has shown effective inhibition of hair growth on living human skin tissue in vitro but this is the first time it has been used in man. Treatment of around […]

December 16, 2015

Approval to Start Clinical Study

Today Follicum obtained approval from the BfArM (the Federal Institute for Drugs and Medical Devices in Germany) and the research ethics committee to start a clinical Phase I/II a study. The study will now proceed according to the previously communicated plan. The study will be performed by the Clinical Research Center for Hair and Skin […]

November 30, 2015

Interim Report Q3 2015

Follicum today reported publication of its Q3 2015 interim report in Swedish. Below is a short summary of activities during the period: Significant activities during third quarter 2015: -On 1 September the company announced that the two toxicity studies which had been ongoing since March were completed, showing positive results. -In September Follicum initiated a collaboration […]